Last year marked the first time in Pfizer’s 175-year history that the drugmaker shelled out the requisite millions for ...

Pfizer (PFE) stock is up today after the pharmaceutical company reported earnings for the fourth quarter of 2024. The company’s adjusted EPS of 63 cents beat Wall Street’s estimate of 47 cents ...

Pfizer Inc. closed 18.10% below its 52-week high of $31.54, which the company reached on July 30th.

Bullish option flow detected in Pfizer (PFE) with 33,534 calls trading, 1.3x expected, and implied vol increasing over 1 point to 27.48%. 2/7 weekly 25 calls and 2/7 weekly 27.5 calls are the most ...

Today's call is being recorded. At this time, I would like to turn the call over to Francesca DeMartino, chief investor relations officer and senior vice president. Please go ahead, ma'am.Francesca ...

BMO Capital markets analyst Evan Seigerman said Pfizer's forecast is already conservative, and with COVID products no longer seen as a core business, investor reaction to lower volumes could be muted.

Pfizer stock (NYSE: PFE) recently reported its Q4 results, with revenues and earnings exceeding the street estimates. The company reported revenue of $17.8 billion and adjusted earnings of $0.63 ...

Jan 13 (Reuters) - U.S. drugmaker Pfizer (PFE.N), opens new tab is going "all in" to develop its experimental obesity drug and has been recruiting more experts in that area, Chief Executive ...

“Pfizer is the best company in executing, there is no one like the Pfizer machine in getting things done,” he said. “What we did with Covid is just an example of that, but it is a very ...

While presenting at the JP Morgan Healthcare Conference, Pfizer Inc. (NYSE:PFE) Albert Bourla, Chairman and CEO, said, “I think we did significant transformative changes in Pfizer.” ...

Pfizer saved $4 billion, plans $1.5 billion more in margin improvements, and issued $7 billion in dividends in nine months. Acquisitions are projected to offset $17 billion-18 billion in revenue ...

NEW YORK (Reuters) - Pfizer on Tuesday appealed a federal judge's refusal to award the drugmaker $75.2 million from a more than decade-old insider trading settlement involving billionaire Steven A.